BiomX Acquires Adaptive Phage Therapeutics
March 18, 2024
BiomX Inc. completed a stock-for-stock acquisition of Adaptive Phage Therapeutics (APT), making APT a wholly owned subsidiary and combining phage therapy capabilities and pipelines. Concurrently, BiomX raised $50 million in a private placement led by affiliates of Deerfield Management and the AMR Action Fund to advance two Phase 2 assets (BX004 and BX211) toward pivotal readouts in 2025–2026.
- Buyers
- BiomX Inc.
- Targets
- Adaptive Phage Therapeutics, Inc.
- Industry
- Biotechnology
- Location
- Maryland, United States
- Transaction Type
- Buyout
Explore More
Related Acquisitions
-
BioPhorum Acquires PharmaX Solutions
May 7, 2026
IT Services
BioPhorum has acquired PharmaX Solutions, a consultancy specializing in digital transformation and end-to-end digital manufacturing solutions for pharmaceutical manufacturing environments. The acquisition expands BioPhorum’s Implementation Services offering and extends its international footprint across offices in Germany, Spain, Denmark, and Switzerland.
-
XTL Biopharmaceuticals to Acquire Psyga Bio to Build Psychedelic Biotechnology Platform
April 30, 2026
Biotechnology
XTL Biopharmaceuticals has entered into a definitive share purchase agreement to acquire 100% of Psyga Bio. The deal is structured as a share exchange with no cash consideration at closing, with XTL issuing ADSs representing 40% of Psyga Bio’s issued and outstanding share capital plus milestone-based ADSs up to an additional 10%.
-
Aditxt Acquires Appili Therapeutics
October 10, 2024
Healthcare Services
Aditxt, Inc. announced that Appili Therapeutics shareholders will vote on a proposed acquisition of all issued and outstanding shares of Appili through a plan of arrangement. Appili’s board recommended shareholders vote in favor, and Aditxt intends to use Appili’s infectious disease pipeline (including the FDA-approved LIKMEZ) to expand its reach in combating life-threatening infections and biodefense threats.
-
PacBio to Acquire Apton Biosystems in Deal Up to $110 Million
August 2, 2023
Biotechnology
PacBio entered into an agreement to acquire Apton Biosystems, a Bay Area company developing a high-throughput short-read sequencer based on advanced optics, image processing, and clustering/chemistry. PacBio plans to integrate its Sequencing by Binding (SBB) short-read chemistry into Apton’s high-throughput instrument to accelerate development and commercialize a differentiated short-read platform.
-
Aditxt Signs Share Exchange Agreement to Acquire AiPharma Global Holdings
December 28, 2021
Healthcare Services
Aditxt (Nasdaq: ADTX) signed a share exchange agreement to acquire AiPharma Global Holdings LLC (AiPharma Global) in a two-step transaction involving an initial closing and a secondary closing, subject to conditions including regulatory, board, shareholder, and Nasdaq approvals. The deal would give Aditxt 9.5% of AiPharma at the initial closing and the remaining 90.5% at the secondary closing, with cash payments and Aditxt share issuance at each step.
-
Pfizer Acquires Amplyx Pharmaceuticals
April 28, 2021
Biotechnology
Pfizer Inc. acquired Amplyx Pharmaceuticals, a privately held clinical-stage biotechnology company developing the antifungal candidate fosmanogepix (APX001). The deal expands Pfizer's anti-infectives pipeline and secures Amplyx's lead and early-stage assets to advance development of novel antifungal and antiviral therapies.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.